CHICAGO ISLET CONSORTIUM ICR AT UIC

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。描述(申请人提供)：I型糖尿病是由于身体不能产生胰岛素引起的，胰岛素是一种荷尔蒙，可以“解锁”身体的细胞，允许葡萄糖进入细胞并为其提供燃料。据估计，2080万美国人患有糖尿病；I型糖尿病占病例的5%至10%(约156万I型糖尿病患者)。严格控制血糖水平是预防或减少I型糖尿病慢性并发症，如失明、肾功能衰竭和心血管疾病的最有效方法。胰岛移植可以实现I型糖尿病患者的胰岛素独立、血糖控制和无低血糖发作。然而，从身体供体胰腺中恢复功能性胰岛是一个复杂的过程，需要优化。在获得无限来源的人胰岛细胞之前，用于治疗糖尿病的内分泌替代疗法的进一步发展将完全依赖于临床应用和实验室研究的高质量胰岛制剂的可用性。由于胰岛隔离程序的复杂性，最好将专有技术集中在有限数量的中心或联合体中，以便最大限度地利用可用资源。该应用程序的目的是将伊利诺伊大学和芝加哥胰岛联盟现有的人类胰岛核心设施扩展为联邦资助的胰岛细胞资源中心，以分离、纯化、鉴定和分配人类胰岛细胞，用于移植到糖尿病患者体内，并用于更大社区的实验室研究。UIC的ICR及其在芝加哥胰岛联盟的合作伙伴将负责整个胰腺的采购、胰岛细胞制剂的分离和质量控制，以及为经批准的研究或临床方案分配胰岛。UIC的ICR正在进行研究和开发，以改进分离技术、细胞活性和功能以及运输程序，并正在研究改进胰岛质量、成分、质量和活性评估的方法。此外，最重要的是，为了这一领域的进步，UIC的ICR将继续为糖尿病患者的移植提供大量高质量的胰岛制剂。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. DESCRIPTION (provided by applicant): Type I diabetes results from the body's failure to produce insulin, the hormone that "unlocks" the cells of the body, allowing glucose to enter and fuel them. It is estimated that 20.8 Million Americans have diabetes; type I diabetes accounts for 5 to 10% of cases (approximately 1.56 Million type I diabetic patients). Keeping blood glucose levels under tight control represents the most effective way either to prevent the onset or to reduce the progression of the chronic complications of type I diabetes, such as blindness, kidney failure and cardiovascular diseases. Islet transplantation can achieve insulin independence, glucose control and freedom of hypoglycemic attacks in patients afflicted with Type I diabetes mellitus. However, the recovery of functional pancreatic islets from cadaveric donor pancreata is a complex procedure and needs to be optimized. Until an unlimited source of human pancreatic islet cell becomes available, the further development of endocrine replacement therapy for the treatment of diabetes will solely depend on the availability of high quality islet preparations, both for clinical application and laboratory-based research. Because of the complexity of the islet isolation procedure, it would be desirable to concentrate the know-how in a limited number of centers or consortiums to allow for optimal use of available resources. The aim of this application is to extend the existing human islet core facility at the University of Illinois and the Chicago Islet Consortium into a federally funded Islet Cell Resource Center to isolate, purify, characterize and distribute human pancreatic islet cells for both transplantation into diabetic patients and use in laboratory studies to a larger community. The ICR at UIC with its partners in the Chicago Islet Consortium will be responsible for the procurement of whole pancreata, isolation and quality control of islet cell preparations, and distribution of islets for approved research or clinical protocols. The ICR at UIC is conducting research and development to improve isolation techniques, cellular viability and function, and shipping procedures, and is investigating methods for improved assessment of islet mass, composition, quality and viability. In addition, and most importantly for the progress of the field, the ICR at UIC will continue to provide large numbers of high-quality islet preparations for transplantation in diabetic patients.